Document:

QuickLinks
 -- Click here to rapidly navigate through this document

 
 

Exhibit 4.5    
    

 
 

COMMON STOCK AND WARRANT PURCHASE AGREEMENT    
    

        This Common Stock and Warrant Purchase Agreement (this "Agreement") is made as of February 9, 2004, by and among Vista Medical Technologies, Inc., a
Delaware corporation (the "Company"), and the individuals and/or entities set forth on Schedule A, attached hereto (each, an "Investor" and,
collectively, the "Investors"). The Company and each Investor, severally and not jointly, hereby agree as follows: 

        1.     Purchase and Sale of Common Stock and Warrants.

        1.1   Sale and Issuance of Common Stock and Warrants.

        (a)   The
Company has duly authorized the sale and issuance, pursuant to the terms of this Agreement, of (i) up to 800,000 shares of the Company's Common Stock, par
value $0.01 per share (the "Common Stock") (the "Maximum Common Stock Shares"), and (ii) Common Stock Purchase Warrants in substantially the form attached hereto as  Exhibit A (each, a
"Warrant" and collectively, the "Warrants") exercisable for up to an aggregate of 400,000 shares of Common Stock (such number
subject to adjustment pursuant to the Warrants) to be issued upon exercise of the Warrants (the "Maximum Warrant Shares"). 

        (b)   Subject
to the terms and conditions of this Agreement, the Investors agree, severally and not jointly, to purchase at the Initial Closing and the Company agrees to sell
and issue to the Investors at the Initial Closing, for an aggregate price per Unit (as defined below) of $2.68, (i) that number of shares of Common Stock set forth opposite such Investor's name
on Schedule A hereto under the column "Shares of Common Stock" and (ii) a Warrant to purchase up to that number of shares of Common Stock
set forth opposite such Investor's name on Schedule A under the column "Shares of Common Stock Underlying Warrant." 

        (c)   Subject
to the terms and conditions of this Agreement, each Additional Investor (as defined below) agrees, severally and not jointly, to purchase at the applicable
Additional Closing (as defined below) and the Company agrees to sell and issue to such Additional Investor at such Additional Closing, for an aggregate price per Unit of $2.68, (i) that number
of shares of Common Stock set forth opposite such Investor's name on Schedule A hereto under the column "Shares of Common Stock" and
(ii) a Warrant to purchase up to that number of shares of Common Stock set forth opposite such Investor's name on Schedule A under the
column "Shares of Common Stock Underlying Warrant." 

        (d)   For
purposes of this Agreement, a "Unit" shall consist of two shares of Common Stock and one warrant to purchase one share of Common Stock. 

        1.2   Initial Closing; Additional Closings.

        (a)   Initial Closing. The initial purchase and sale of the Common Stock and Warrants to the Investors shall take place at the
offices of Heller Ehrman White &McAuliffe, LLP, 4350 La Jolla Village Drive, San Diego, California, by an exchange of executed counterpart signature pages of this Agreement, a Warrant and the
Registration Rights Agreement (as defined below), at 10:00 A.M., on February 9, 2004, or at such other time and place as the Company and the Investors mutually agree upon orally or in
writing (which time and place are designated as the "Initial Closing"). At the Initial Closing, the Company shall deliver to the Investors a certificate representing the Common Stock and Warrant each
Investor is purchasing, each duly executed, against payment of the aggregate purchase price therefor by check, wire transfer or any combination thereof. 

        (b)   Additional Closings. The Company may sell, at any time and from time to time prior to the date which is
forty-five (45) days following the Initial Closing (each, an "Additional Closing"), up to the Maximum Common Stock Shares and Maximum Warrant Shares (including Common Stock and
Warrants sold in connection with the Initial Closing) to such purchasers as are acceptable to the Company (each, an "Additional Investor" and, collectively, the "Additional Investors") on the terms
set 

 

forth
in Section 1.1(c) hereof, by an exchange of executed counterpart signature pages of this Agreement, a Warrant and the Registration Rights Agreement. Each Additional Investor, upon
delivery to the Company of such counterpart signature pages, shall become a party to and be bound by this Agreement, such Additional Investor's Warrant and the Registration Rights Agreement and shall
have the rights and obligations hereunder and thereunder each to the same extent as if they were an original Investor; provided, however, that the
representations and warranties of each Additional Investor set forth in Section 3 hereof shall speak as of the applicable Additional Closing.  Schedule A shall be appropriately revised to
reflect each Additional Investor and the purchase of Common Stock and Warrant by such Additional
Investor. 

        2.     Representations and Warranties of the Company. The Company hereby represents and warrants to each Investor as follows: 

        2.1   Organization, Good Standing and Qualification. The Company is a corporation duly organized, validly existing and in good
standing under the laws of the State of Delaware and has all requisite corporate power and authority to carry on its business as now conducted and as proposed to be conducted and to execute and
deliver this Agreement and to carry out and perform its obligations under the terms of this Agreement. The Company is duly qualified to transact business and is in good standing in each jurisdiction
in which the failure so to qualify would have a material and adverse effect on the operation of its business or properties. 

        2.2   Authorization. All corporate action on the part of the Company and its officers, directors and stockholders necessary for
the authorization, execution and delivery of this Agreement, the Warrants and the Registration Rights Agreement, and the performance of all obligations of the Company hereunder and thereunder, has
been taken or will be taken prior to the Initial Closing; and this Agreement, the Warrants and the Registration Rights Agreement constitute valid and legally binding obligations of the Company,
enforceable against the Company in accordance with their respective terms, except (a) as limited by applicable bankruptcy, insolvency, reorganization, moratorium and other laws of general
application affecting enforcement of creditors' rights generally, (b) as limited by laws relating to the availability of specific performance, injunctive relief or other equitable remedies, and
(c) to the extent the indemnification provisions, if any, contained in any of such documents may be limited by applicable federal or state securities laws. The issuance of the Common Stock and
Warrants pursuant to the provisions of this Agreement will not violate any preemptive rights or rights of first refusal granted by the Company, and will be free of any liens or encumbrances, other
than any liens or encumbrances created by or imposed upon the Investors through no action of the Company; provided, however, that the Common Stock and
Warrants (and the securities issuable upon exercise of the Warrants) may be subject to restrictions on transfer pursuant to the terms of this Agreement and the Warrants and under state and/or federal
securities laws as set forth herein or as otherwise required by such laws at the time the transfer is proposed. 

        2.3   Government Consents. All consents, approvals, orders, or authorizations of, or registrations, qualifications,
designations, declarations, or filings with, any governmental authority, required on the part of the Company in connection with the valid execution and delivery of this Agreement, the offer, sale or
issuance of the Common Stock and Warrants, and the equity securities issuable upon exercise of the Warrants, and the consummation of any other transaction contemplated hereby shall have been obtained
and will be effective at the Initial Closing, except for notices required or permitted to be filed with certain state and federal securities commissions, which notices will be filed on a timely basis. 

        2.4   Offering. Assuming the accuracy of the representations and warranties of each Investor contained in Section 3
hereof, the offer, issue, and sale of the Common Stock and Warrants are exempt from the registration and prospectus delivery requirements of the Securities Act of 1933, as amended (the "Act"), and the
registration or qualification requirements of all applicable state securities laws. 

2

 

Neither
the Company nor any authorized agent acting on its behalf will take any action hereafter that would cause the loss of such exemptions. 

        2.5   Litigation. There is no action, suit, proceeding, or investigation pending or, to the Company's knowledge, currently
threatened in writing against the Company that questions the validity of this Agreement, the Warrants or the Registration Rights Agreement or the right of the Company to issue the Common Sock and
Warrants or to enter into such agreements or to consummate the transactions contemplated hereby and thereby. The Company is not a party to and, to the best of its knowledge, is not named in any order,
writ, injunction, judgment, or decree of any court, government agency, or instrumentality which might result either individually or in the aggregate, in any material and adverse change in the assets,
business, properties, prospects, or financial condition of the Company. There is no action, suit or preceding by the Company currently pending or that the Company currently intends to initiate. 

        2.6   Public Filings. The reports and documents filed by the Company under Section 13 or subsections (a) or
(c) of Section 14 of the Securities Exchange Act of 1934, as amended (the "Exchange Act") with the Securities and Exchange Commission (the "SEC") since January 1, 2003 (such
reports, collectively, the "Company Reports") constitute all of the reports and documents required to be filed by the Company under Section 13 or subsections (a) or (c) of
Section 14 of the Exchange Act with the SEC from January 1, 2003 through the date hereof. The Company Reports have been duly and timely filed, were in compliance in all material respects
with the requirements of the Exchange Act and the rules and regulations thereunder when filed, and were complete and correct in all material respects as of the dates at which the information therein
was furnished. 

        2.7   Disclosure. The Company and the Investors have engaged in a due diligence process, and in connection with that process
the Company has made available to the Investors all the information reasonably available to the Company that the Investors have requested in connection with deciding whether to acquire the Common
Stock, the Warrants and the Common Stock underlying the Warrants, and all information that, to the Company's knowledge, is reasonably necessary to enable the Investors to make such a decision,
including delivery of that certain private placement memorandum containing projections describing its proposed business (collectively, the "Business Plan"). Assuming the accuracy of the Investors'
representations regarding their sophistication with respect to investments in companies similar to the Company and in light of the due diligence process mentioned above, to the Company's knowledge, no
representation or warranty of the Company contained in this Agreement or the Business Plan (when read together) contains any untrue statement of a material fact or omits to state a material fact
necessary in order to make the statements contained herein or therein not misleading in light of the circumstances under which they were made. To the extent the Business Plan was prepared by
management of the Company, the Business Plan and the financial and other projections contained in the Business Plan were prepared in good faith; however, the Company does not warrant that it will
achieve such projections. It is understood that this representation is qualified by the fact that, while the Company has delivered to the Investors what is titled a "private placement memorandum," it
does not contain "Management's Discussion and Analysis of Financial Condition and Results of Operations" of the type typically contained therein. 

        3.     Representations and Warranties of the Investors. The Investors hereby represent, warrant and covenant to the Company as of
the Initial Closing, and each Additional Investor hereby represents, warrants and covenants to the Company, severally and not jointly, as of the applicable Additional Closing, that: 

        3.1   Authorization. Such Investor has full power and authority to enter into this Agreement, such Investor's Warrant and the
Registration Rights Agreement, and each such agreement constitutes a valid and legally binding obligation of such Investor, enforceable in accordance with its terms, except (i) as limited by
applicable bankruptcy, insolvency, reorganization, moratorium and other laws of general 

3

 

application
affecting enforcement of creditors' rights generally, (ii) as limited by laws relating to the availability of specific performance, injunctive relief or other equitable remedies,
and (iii) to the extent the indemnification provisions contained in the Registration Rights Agreement may be limited by applicable federal or state securities laws. 

        3.2   Purchase Entirely for Own Account. This Agreement is made with such Investor in reliance upon such Investor's
representation to the Company, which by such Investor's execution of this Agreement such Investor hereby confirms, that the Common Stock and Warrant to be received by such Investor and the Common
Stock issuable upon exercise of such Warrant (collectively, the "Securities") will be acquired for investment for such Investor's own account, not as a nominee or agent, and not with a view to the
resale or distribution of any part thereof, and that such Investor has no present intention of selling, granting any participation in or otherwise distributing the same. By executing this Agreement,
such Investor further represents that such Investor does not have any contract, undertaking, agreement or arrangement with any person to sell, transfer or grant participations to such person or to any
third person, with respect to any of the Securities. 

        3.3   Disclosure of Information. Such Investor believes it has received all information it considers necessary or appropriate
for deciding whether to purchase the Securities. Such Investor further represents that it has had an opportunity to ask questions and receive answers from the Company regarding the terms and
conditions of the offering of the Securities and the business, properties, prospects and financial condition of the Company. The foregoing, however, does not limit or modify the representations and
warranties of the Company in Section 2 of this Agreement or the right of each Investor to rely thereon. 

        3.4   Investment Experience. Such Investor is an investor in securities of companies in the development stage and acknowledges
that it is able to fend for itself, can bear the economic risk of its investment, and has such knowledge and experience in financial or business matters that it is capable of evaluating the merits and
risks of the investment in the Securities. If other than an individual, such Investor also represents it has not been organized for the purpose of acquiring the Securities. 

        3.5   Accredited Investor. Such Investor is an "accredited investor" within the meaning of Securities and Exchange Commission
("SEC") Rule 501 of Regulation D, as presently in effect. 

        3.6   Restricted Securities. Such Investor understands that the Securities such Investor is purchasing are each characterized
as a "restricted security" under federal securities laws inasmuch as they are being acquired from the Company in a transaction not involving a public offering and that under such laws and applicable
regulations none of the Securities may be resold without registration under the Act, except in certain limited circumstances. In the absence of an effective registration statement covering the
Securities or an available exemption from registration under the Act, the Securities must be held indefinitely. In this connection, such Investor represents that it is familiar with SEC
Rule 144, as presently in effect, and understands the resale limitations imposed thereby and by the Act, including without limitation the Rule 144 condition that current information
about the Company be available to the public. 

        3.7   Further Limitations on Disposition. Without in any way limiting the representations set forth above, such Investor
further agrees not to make any disposition of all or any portion of the Securities unless and until: 

        (a)   There
is then in effect a registration statement under the Act covering such proposed disposition and such disposition is made in accordance with such registration
statement; or 

        (b)   (i) Such
Investor shall have notified the Company in writing of the proposed disposition and shall have furnished the Company in writing with a detailed statement
of the circumstances surrounding the proposed disposition, (ii) if requested by the Company, such Investor shall have furnished the Company with an opinion of counsel, satisfactory to the
Company, that such disposition will not require 

4

 

registration
of such shares under the Act and (iii) the transferee shall agree in writing to be bound by this Section 3 as if an original Investor. It is agreed that the Company will not
require opinions of counsel pursuant to Section 3.7(b)(ii) or that the transferee be bound pursuant to Section 3.7(b)(iii) for dispositions made pursuant to
Rule 144, except (i) in unusual circumstances or (ii) at the request of the Company's transfer agent. 

        3.8   Legends. It is understood that, until registered under an effective registration statement under the Act, the
certificates evidencing the Securities may bear one or all of the following or other applicable legends: 

        (a)   "The
securities represented by this certificate have not been registered under the Securities Act of 1933, as amended. They may not be sold, offered for sale, pledged or
hypothecated in the absence of a registration statement in effect with respect to the securities under such Act or an opinion of counsel satisfactory to the Company that such registration is not
required or unless sold pursuant to Rule 144 of such Act." 

        (b)   Any
legend required by the laws of the State of California, including any legend required by the California Department of Corporations and Sections 417 and 418 of the
California Corporations Code. 

        3.9   Tax Advisors. Such Investor is relying solely on its own tax advisors and understands that each such Investor (and not
the Company) shall be responsible for such Investor's own tax liability that may arise as a result of this investment or the transactions contemplated by this Agreement. 

        4.     California Commissioner of Corporations. 

        4.1   Corporate Securities Law. THE SALE OF THE SECURITIES THAT ARE THE SUBJECT OF THIS AGREEMENT HAS NOT BEEN QUALIFIED WITH
THE COMMISSIONER OF CORPORATIONS OF THE STATE OF CALIFORNIA AND THE ISSUANCE OF SUCH SECURITIES OR THE PAYMENT OR RECEIPT OF ANY PART OF THE CONSIDERATION FOR SUCH SECURITIES PRIOR TO SUCH
QUALIFICATION IS UNLAWFUL, UNLESS THE SALE OF SECURITIES IS EXEMPT FROM QUALIFICATION BY SECTION 25100, 25102 OR 25105 OF THE CALIFORNIA CORPORATIONS CODE. THE RIGHTS OF ALL PARTIES TO THIS AGREEMENT
ARE EXPRESSLY CONDITIONED UPON SUCH QUALIFICATION BEING OBTAINED, UNLESS THE SALE IS SO EXEMPT. 

        5.     Conditions of Investors' Obligations at Closing. The obligations of the Investors under Section 1 of this Agreement
are subject to the fulfillment on or before the Initial Closing of each of the following conditions: 

        5.1   Registration Rights Agreement. The Company and each Investor participating in the Initial Closing shall have entered into
the Registration Rights Agreement in substantially the form attached hereto as Exhibit B (the "Registration Rights Agreement"). 

        5.2   Warrants. The Company shall have executed in favor of each Investor participating in the Initial Closing an appropriate
Warrant. 

        6.     Conditions of the Company's Obligations at Closing. The obligations of the Company under this Agreement are subject to the
fulfillment on or before the Initial Closing and each Additional Closing of each of the following conditions by the Investors, as applicable: 

        6.1   Payment of Purchase Price. Each Investor shall have delivered the purchase price specified in Section 1. 

        6.2   Registration Rights Agreement. The Company and each Investor participating in the Initial Closing shall have entered into
the Registration Rights Agreement. 

5

 

        7.     Miscellaneous. 

        7.1   Survival. The warranties, representations and covenants of the Company and Investors contained in or made pursuant to
this Agreement shall survive the execution and delivery of this Agreement, the Initial Closing and each Additional Closing for a period of one year. 

        7.2   Successors and Assigns. Except as otherwise provided herein, the terms and conditions of this Agreement shall inure to
the benefit of and be binding upon the respective successors and assigns of the parties (including transferees of any Securities). Nothing in this Agreement, express or implied, is intended to confer
upon any party, other than the parties hereto or their respective successors and assigns, any rights, remedies, obligations or liabilities under or by reason of this Agreement, except as expressly
provided in this Agreement. 

        7.3   Governing Law. This Agreement shall be governed by and construed under the laws of the State of California as applied to
agreements among California residents entered into and to be performed entirely within California. 

        7.4   Titles and Subtitles. The titles and subtitles used in this Agreement are used for convenience only and are not to be
considered in construing or interpreting this Agreement. 

        7.5   Notices. Unless otherwise provided herein, all notices required or permitted hereunder shall be in writing and shall be
deemed effectively given: (i) upon personal delivery to the party to be notified, (ii) when sent by confirmed facsimile if sent during the normal business hours of the recipient (if not
sent during the normal business hours of the recipient, then on the next business day); (iii) five days after having been sent by registered or certified mail, return receipt requested, postage
prepaid; or (iv) one day after deposit with a nationally recognized overnight courier, specifying next day delivery, with written verification of receipt. All written communications shall be
addressed to the party to be notified at the address or number applicable to such party appearing on the books of the Company. 

        7.6   Finder's Fee. Each party represents that it neither is nor will be obligated for any finders' fee or commission in
connection with the transactions contemplated by this Agreement, the Warrants or the Registration Rights Agreement. Each Investor agrees to indemnify and to hold harmless the Company from any
liability for any commission or compensation in the nature of a finders' fee (and the costs and expenses of defending against such liability or asserted liability) for which such Investor or any of
its officers, partners, employees or representatives is responsible. The Company agrees to indemnify and hold harmless each Investor from any liability for any commission or compensation in the nature
of a finders' fee (and the costs and expenses of defending against such liability or asserted liability) for which the Company or any of its officers, employees or representatives is responsible. 

        7.7   Attorney's Fees. If any action at law or in equity is necessary to enforce or interpret the terms of this Agreement, the
Warrants or the Registration Rights Agreement, the prevailing party shall be entitled to reasonable attorney's fees, costs and necessary disbursements in addition to any other relief to which such
party may be entitled. 

        7.8   Amendments and Waivers. Any term of this Agreement may be amended and the observance of any term of this Agreement may be
waived (either generally or in a particular instance and either retroactively or prospectively) only with the written consent of the Company and the Investors (or their permitted assignees) holding a
majority of the Common Stock (not including Common Stock issued or issuable upon exercise of Warrants) sold pursuant to this Agreement. Any such amendment or waiver effected in accordance with this
paragraph shall be binding upon all the Investors, each transferee of the Securities and the Company. 

        7.9   Severability. If one or more provisions of this Agreement are held to be unenforceable under applicable law, such
provision shall be excluded from this Agreement and the balance of the 

6

 

Agreement
shall be interpreted as if such provision were so excluded and shall be enforceable in accordance with its terms. 

        7.10 Entire Agreement. This Agreement, the Warrants and the Registration Rights Agreement (including the exhibits and
schedules hereto and thereto) constitute the entire agreement among the parties with respect to the subject matter hereof and thereof and no party shall be liable or bound to any other party in any
manner by any warranties, representations or covenants except as specifically set forth herein or therein. 

        7.11 Counterparts. This Agreement may be executed in one or more counterparts, each of which shall be deemed an original, but
all of which together shall constitute one and the same instrument. Each Additional Investor shall execute a counterpart signature page to this Agreement and become a party to this Agreement without
the need of further signature or approval of any Investor (as contemplated by Section 1.2(b) hereof). 

[Signature
pages follow] 

7

        The parties hereto have executed this Common Stock and Warrant Purchase Agreement as of the date first written above. 

	COMPANY:	 	 	 	VISTA MEDICAL TECHNOLOGIES, INC.
	

 	
 	

 	
 	

By:	

/s/  JOHN R. LYON      
 John R. Lyon, President and Chief Executive Officer
	

 	
 	

Address:	
 	

2101 Faraday Ave.

Carlsbad, CA 92008
	 	 	Fax:	 	(760) 603-9170

[COUNTERPART
SIGNATURE PAGE TO COMMON STOCK AND WARRANT

PURCHASE AGREEMENT OF VISTA MEDICAL TECHNOLOGIES, INC.] 

        The
parties hereto have executed this Common Stock and Warrant Purchase Agreement as of the date first written above. 

	INVESTORS:	 	 	 
	

 	
 	

 	

/s/  ALBERT GRUNEISEN III      
 Albert Gruneisen III
	

 	
 	

Address:	

1626 Cherokee Road

Louisville, KY 40205
	

 	
 	

Telephone:	

(502) 589-4523

[COUNTERPART
SIGNATURE PAGE TO COMMON STOCK AND WARRANT

PURCHASE AGREEMENT OF VISTA MEDICAL TECHNOLOGIES, INC.] 

        The
parties hereto have executed this Common Stock and Warrant Purchase Agreement as of the date first written above. 

	 	 	 	/s/  WILLIAM C. DUGDALE      
 William C. Dugdale
	

 	
 	

Address:	

1907 Mount Vernon Avenue

Wilmington, DE 19806
	

 	
 	

Telephone:	

(302) 777-5445

[COUNTERPART
SIGNATURE PAGE TO COMMON STOCK AND WARRANT

PURCHASE AGREEMENT OF VISTA MEDICAL TECHNOLOGIES, INC.] 

        The
parties hereto have executed this Common Stock and Warrant Purchase Agreement as of the date first written above. 

	 	 	 	/s/  TROY N. TOMLIN      
 Troy N. Tomlin
	

 	
 	

Address:	

 
	 	 	 	

	 	 	 	

	

 	
 	

Telephone:	

 
	 	 	 	

[COUNTERPART
SIGNATURE PAGE TO COMMON STOCK AND WARRANT

PURCHASE AGREEMENT OF VISTA MEDICAL TECHNOLOGIES, INC.] 

        The
parties hereto have executed this Common Stock and Warrant Purchase Agreement as of the date first written above. 

	 	 	 	/s/  WILLIAM K. DUGDALE      
 William K. Dugdale
	

 	
 	

Address:	

250 Fairview Road

Coatesville, PA 19320
	

 	
 	

Telephone:	

(302) 652-3101

[COUNTERPART
SIGNATURE PAGE TO COMMON STOCK AND WARRANT

PURCHASE AGREEMENT OF VISTA MEDICAL TECHNOLOGIES, INC.] 

        The
parties hereto have executed this Common Stock and Warrant Purchase Agreement as of the date first written above. 

	 	 	 	/s/  MARGARET L. DUGDALE      
 Margaret L. Dugdale
	

 	
 	

Address:	

2742 Pierce Street

San Francisco, CA 94123
	

 	
 	

Telephone:	

(415) 673-9585

[COUNTERPART
SIGNATURE PAGE TO COMMON STOCK AND WARRANT

PURCHASE AGREEMENT OF VISTA MEDICAL TECHNOLOGIES, INC.] 

        The
parties hereto have executed this Common Stock and Warrant Purchase Agreement as of the date first written above. 

	 	 	 	/s/  DEVON D. HATHAWAY      
 Devon D. Hathaway
	

 	
 	

Address:	

6206 Blackburn Lane

Baltimore, MD 21212
	

 	
 	

Telephone:	

(410) 433-8524

[COUNTERPART
SIGNATURE PAGE TO COMMON STOCK AND WARRANT

PURCHASE AGREEMENT OF VISTA MEDICAL TECHNOLOGIES, INC.] 

        The
parties hereto have executed this Common Stock and Warrant Purchase Agreement as of the date first written above. 

	 	 	 	C. GLEN & JOAN DUGDALE
	

 	
 	

 	

/s/  C. GLEN DUGDALE      
 C. Glen Dugdale
	

 	
 	

 	

/s/  JOAN DUGDALE      
 Joan Dugdale
	

 	
 	

Address:	

P.O. Box 4550

Greenville, DE 19807
	

 	
 	

Telephone:	

(302) 656-0529

[COUNTERPART
SIGNATURE PAGE TO COMMON STOCK AND WARRANT

PURCHASE AGREEMENT OF VISTA MEDICAL TECHNOLOGIES, INC.] 

        The
parties hereto have executed this Common Stock and Warrant Purchase Agreement as of the date first written above. 

	

 	
 	

 	

/s/  JOAN DUGDALE      
 Joan Dugdale
	

 	
 	

Address:	

P.O. Box 4550

Greenville, DE 19807
	

 	
 	

Telephone:	

(302) 656-0529

[COUNTERPART
SIGNATURE PAGE TO COMMON STOCK AND WARRANT

PURCHASE AGREEMENT OF VISTA MEDICAL TECHNOLOGIES, INC.] 

        The
parties hereto have executed this Common Stock and Warrant Purchase Agreement as of the date first written above. 

	 	 	 	 	MBD GST FBO C. GLEN DUGDALE
	

 	
 	

 	
 	

By:	

/s/  C. GLEN DUGDALE      
 C. Glen Dugdale
	

 	
 	

Address:	
 	

P.O. Box 4550

Greenville, DE 19807
	

 	
 	

Telephone:	
 	

(302) 656-0529

[COUNTERPART
SIGNATURE PAGE TO COMMON STOCK AND WARRANT

PURCHASE AGREEMENT OF VISTA MEDICAL TECHNOLOGIES, INC.] 

        The
parties hereto have executed this Common Stock and Warrant Purchase Agreement as of the date first written above. 

	 	 	 	 	B/D TRUST FBO C. GLEN DUGDALE
	

 	
 	

 	
 	

By:	

/s/  C. GLEN DUGDALE      
 C. Glen Dugdale
	

 	
 	

Address:	
 	

P.O. Box 4550

Greenville, DE 19807
	

 	
 	

Telephone:	
 	

(302) 656-0529

[COUNTERPART
SIGNATURE PAGE TO COMMON STOCK AND WARRANT

PURCHASE AGREEMENT OF VISTA MEDICAL TECHNOLOGIES, INC.] 

        The
parties hereto have executed this Common Stock and Warrant Purchase Agreement as of the date first written above. 

	 	 	 	 	JOAN CORRIGAN REVOCABLE TRUST
	

 	
 	

 	
 	

By:	

/s/  JOAN CORRIGAN      
 Joan Corrigan, Trustee
	

 	
 	

Address:	
 	

2550 Pierce Street

San Francisco, CA 94115
	

 	
 	

Telephone:	
 	

(415) 346-4666

[COUNTERPART
SIGNATURE PAGE TO COMMON STOCK AND WARRANT

PURCHASE AGREEMENT OF VISTA MEDICAL TECHNOLOGIES, INC.] 

        The
parties hereto have executed this Common Stock and Warrant Purchase Agreement as of the date first written above. 

	 	 	 	JOSEPH AND JUDY YAAKOVIAN
	

 	
 	

 	

/s/  JOSEPH YAAKOVIAN      
 Joseph Yaakovian
	

 	
 	

 	

/s/  JUDY YAAKOVIAN      
 Judy Yaakovian
	

 	
 	

Address:	

1020 Foulk Road

Wilmington, DE 19803
	

 	
 	

Telephone:	

(302) 573-4011

[COUNTERPART
SIGNATURE PAGE TO COMMON STOCK AND WARRANT

PURCHASE AGREEMENT OF VISTA MEDICAL TECHNOLOGIES, INC.] 

 
 

Schedule A    
    SCHEDULE OF INVESTORS    
    

	Investor
 
	 	Share of Common Stock
	 	Shares of Common Stock Underlying Warrant
	 	Aggregate Purchase

Price

	Albert Gruneisen III	 	75,000	 	37,500	 	$	100,500
	William C. Dugdale	 	30,000	 	15,000	 	$	40,200
	Troy N. Tomlin	 	19,000	 	9,500	 	$	25,460
	William K. Dugdale	 	80,000	 	40,000	 	$	107,200
	Margaret L. Dugdale	 	38,000	 	19,000	 	$	50,920
	Devon D. Hathaway	 	30,000	 	15,000	 	$	40,200
	C. Glen & Joan Dugdale	 	22,000	 	11,000	 	$	29,480
	Joan O. Dugdale	 	44,000	 	22,000	 	$	58,960
	MBD GST FBO C. Glen Dugdale	 	22,000	 	11,000	 	$	29,480
	B/D Trust FBO C. Glen Dugdale	 	22,000	 	11,000	 	$	29,480
	Joan Corrigan Revocable Trust	 	38,000	 	19,000	 	$	50,920
	Joseph and Judy Yaakovian	 	19,000	 	9,500	 	$	25,460
	Total	 	 	 	 	 	 	 

[COUNTERPART
SIGNATURE PAGE TO COMMON STOCK AND WARRANT

PURCHASE AGREEMENT OF VISTA MEDICAL TECHNOLOGIES, INC.] 

 
 

Exhibit A    
    FORM OF COMMON STOCK PURCHASE WARRANT    
    

Exhibit A 

 
 

Exhibit B    
    FORM OF REGISTRATION RIGHTS AGREEMENT]    
    

Exhibit B 

QuickLinks

Exhibit 4.5

COMMON STOCK AND WARRANT PURCHASE AGREEMENT

Schedule A SCHEDULE OF INVESTORS

Exhibit A FORM OF COMMON STOCK PURCHASE WARRANT

Exhibit B FORM OF REGISTRATION RIGHTS AGREEMENT]QuickLinks
 -- Click here to rapidly navigate through this document

 
 

Exhibit 4.6    
    

 
 

REGISTRATION RIGHTS AGREEMENT    
    

        This Registration Rights Agreement (this "Agreement") is made as of February 9, 2004 (the "Effective Date"), by and among Vista Medical
Technologies, Inc., a Delaware corporation (the "Company"), and the individuals and/or entities set forth on Schedule A, attached hereto
(each, an "Investor" and, collectively, the "Investors"). 

        WHEREAS,
the Company and the Investors are parties to that certain Common Stock and Warrant Purchase Agreement of even date herewith (the "Purchase Agreement"); 

        WHEREAS,
in order to induce the Company to sell its securities pursuant to the Purchase Agreement, and in order to induce the Investors to invest funds in the Company pursuant to the
Purchase Agreement, the Company and the Investors desire to memorialize the obligation of the Company to register shares of the Company's Common Stock ("Common Stock") issuable to the Investors; 

        NOW,
THEREFORE, in consideration of the mutual promises set forth herein, and other good and valuable consideration the receipt and sufficiency of which are hereby acknowledged, the
Company and the Investors hereby agree as follows: 

	1.
	Registration Rights.

        1.1   Definitions. For purposes of this Section 1: 

        (a)   The
term "register," "registered" and "registration" refer to the act of preparing and filing a registration statement, or similar document, in compliance with the Act
and applicable rules and regulations thereunder, and the declaration or ordering of effectiveness of such registration statement or document. 

        (b)   The
term "Registrable Securities" means (i) the Common Stock sold pursuant to the Purchase Agreement, (ii) the Common Stock issuable or issued upon
exercise of the Warrants (as defined in the Purchase Agreement) sold pursuant to the Purchase Agreement and (iii) the Common Stock issued as (or issuable upon the conversion or exercise of any
warrant, right or other security which is issued as) a dividend or other distribution with respect to, or in exchange for or in replacement of, the shares listed in (i) and (ii), excluding in
all cases, however, any securities sold by a person in a transaction in which rights under this Agreement are not assigned. Notwithstanding the foregoing, such Common Stock or other securities shall
only be treated as Registrable Securities if and so long as they have not been (A) sold to or through a broker or dealer or underwriter in a public distribution or a public securities
transaction or (B) sold in a transaction exempt from the registration and prospectus delivery requirements of the Act under Section 4(1) thereof so that all transfer restrictions, and
restrictive legends with respect thereto, if any, are removed upon the consummation of such sale. 

        (c)   The
term "Form S-3" means such form under the Act as in effect on the date hereof or any registration form under the Act subsequently adopted by the
SEC which permits inclusion or incorporation of substantial information by reference to other documents filed by the Company with the SEC. 

        (d)   The
term "SEC" means the Securities and Exchange Commission. 

        (e)   The
term "Act" means the Securities Act of 1933, as amended. 

        1.2   Form S-3 Registration.

        (a)   The
Company agrees that, within 90 days of the Initial Closing (as defined in the Purchase Agreement), it will prepare and file with the SEC a registration
statement (on Form S-3 or other appropriate form of registration statement) under the Act (the "Registration Statement") so as to permit the public offering and resale of the
Registrable Securities under the Act by the 

 

Investors,
and shall use best efforts to cause the Registration Statement to be declared effective by the SEC. 

        1.3   Obligations of the Company. In connection with Section 1.2(a), the Company shall (except as otherwise provided in
this Agreement), as expeditiously as reasonably possible: 

        (a)   Keep
the Registration Statement effective until the earliest of (i) the date that all shares of Registrable Securities registered on the Registration Statement
have been sold or otherwise disposed of pursuant to the Registration Statement, (ii) the date all shares of Registrable Securities registered on the Registration Statement may be sold under the
provisions of Rule 144 without limitation as to volume and (iii) the date all shares of Registrable Securities registered on the Registration Statement have been otherwise transferred to
persons who may trade such shares without restriction under the Act, and the Company has delivered a new certificate or other evidence of ownership for such securities not bearing a restrictive
legend; provided, however, that an Investor shall, at the request of the Company, refrain from selling any Registrable Securities registered on the
Registration Statement in the event facts or circumstances arise that require additional disclosure in connection with the Registration Statement to comply with the provisions of the Act and the
Company determines in good faith that such disclosure would adversely affect the Company; provided, further, that the Company reserves the right to
suspend effectiveness of the Registration Statement to comply with the Act. 

        (b)   Prepare
and file with the SEC such amendments and supplements to the Registration Statement and the prospectus used in connection with the Registration Statement as may
be necessary to comply with the provisions of the Act with respect to the disposition of all Registrable Securities registered on the Registration Statement until the distribution described in the
Registration Statement is completed; provided, however, that an Investor shall, at the request of the Company, refrain from selling any securities
included in the Registration Statement in the event facts or circumstances arise that require additional disclosure in connection with the Registration Statement to comply with the provisions of the
Act and the Company determines in good faith that such disclosure would adversely affect the Company; provided, further, that the Company reserves the
right to suspend effectiveness of the Registration Statement to comply with the Act. 

        (c)   Furnish
to the Investors such number of copies of a prospectus, including a preliminary prospectus, in conformity with the requirements of the Act, and such other
documents as they may reasonably request in order to facilitate the disposition of the Registrable Securities registered on the Registration Statement. 

        (d)   Use
its best efforts to register and qualify the Registrable Securities registered on the Registration Statement under such other securities or Blue Sky laws of such
jurisdictions as shall be reasonably requested by the Investors; provided, however, that the Company shall not be required in connection therewith or as
a condition thereto to qualify to do business or to file a general consent to service of process in any such states or jurisdictions. 

        (e)   Notify
each Investor with Registrable Securities registered on the Registration Statement at any time when a prospectus relating thereto is required to be delivered
under the Act of the happening of any event the result of which causes the prospectus included in the Registration Statement, as then in effect, to include an untrue statement of a material fact or
omit to state a material fact required to be stated therein or necessary to make the statements therein not misleading in light of the circumstances then existing. 

        (f)    Cause
all Registrable Securities registered on the Registration Statement to be listed on each securities exchange on which similar securities issued by the Company are
then listed. 

2

 

        (g)   Provide
a transfer agent and registrar for all Registrable Securities registered on the Registration Statement and a CUSIP number for all such Registrable Securities, in
each case not later than the effective date of such Registration Statement. 

        1.4   Furnish Information. It shall be a condition precedent to the obligations of the Company to take any action pursuant to
this Section 1 that the Investors cooperate with the Company in all respects in connection with this Agreement, including timely supplying all information reasonably requested by the Company
(which shall include all information regarding the Investors and proposed manner of sale of all Registrable Securities registered on the Registration Statement) and executing and returning all
documents reasonably requested in connection with the registration and sale of the Registrable Securities registered on the Registration Statement. Each Investor with Registrable Securities registered
on such Registration Statement shall consent to be named as an underwriter in such Registration Statement. 

        1.5   Expenses of Registration. All expenses (other than underwriting discounts and commissions) incurred in connection with
any registrations, filings or qualifications of Registrable Securities pursuant to this Agreement, including (without limitation) all registration, filing and qualification fees, printers' and
accounting fees and fees and disbursements of counsel for the Company, shall be borne by the Company. The Investors shall bear the cost of underwriting and/or brokerage discounts, fees and
commissions, if any, applicable to all Registrable Securities registered on the Registration Statement and the fees and expenses of Investors' counsel. 

        1.8   Delay of Registration. No Investor shall have any right to obtain or seek an injunction restraining or otherwise delaying
any such registration as the result of any controversy that might arise with respect to the interpretation or implementation of this Section 1. 

        1.9   Indemnification. In the event any Registrable Securities are included in a registration statement under this
Section 1: 

        (a)   To
the extent permitted by law, the Company will indemnify and hold harmless each Investor, any underwriter (as defined in the Act) for such Investor and each person, if
any, who controls such Investor or underwriter within the meaning of the Act or the Securities Exchange Act of 1934, as amended (the "1934 Act"), against any losses, claims, damages or liabilities
(joint or several) to which they may become subject under the Act, or the 1934 Act, insofar as such losses, claims, damages or liabilities (or actions in respect thereof) arise out of or are based
upon any of the following statements, omissions or violations (collectively, a "Violation"): (i) any untrue statement or alleged untrue statement of a material fact contained in such
registration statement, including any preliminary prospectus or final prospectus contained therein or any amendments or supplements thereto, (ii) the omission or alleged omission to state
therein a material fact required to be stated therein, or necessary to make the statements therein not misleading, or (iii) any violation or alleged violation by the Company of the Act, the
1934 Act, or any rule or regulation promulgated under the Act or the 1934 Act or any state securities law in connection with the offering covered by such Registration Statement; and the Company will
pay to each such Investor, underwriter or controlling person, as incurred, any legal or other expenses reasonably incurred by them in connection with investigating or defending any such loss, claim,
damage, liability or action; provided, however, that the indemnity agreement contained in this subsection 1.9(a) shall not apply to amounts paid in
settlement of any such loss, claim, damage, liability, or action if such settlement is effected without the consent of the Company (which consent shall not be unreasonably withheld), nor shall the
Company be liable to any Investor, underwriter or controlling person for any such loss, claim, damage, liability or action to the extent that it arises out of or is based upon a Violation which occurs
in reliance upon and in conformity with written information furnished expressly for use in connection with such registration by any such Investor, underwriter or controlling person. 

3

 

        (b)   To
the extent permitted by law, each selling Investor will indemnify and hold harmless the Company, each of its directors, each of its officers who has signed the
registration statement, each person, if any, who controls the Company within the meaning of the Act, any underwriter, any other Investor selling securities in such registration statement and any
controlling person of any such underwriter or other Investor, against any losses, claims, damages or liabilities (joint or several) to which any of the foregoing persons may become subject under the
Act or the 1934 Act or any state securities law in connection with the offering covered by such Registration Statement insofar as such losses, claims, damages or liabilities (or actions in respect
thereto) arise out of or are based upon any Violation, in each case to the extent (and only to the extent) that such Violation occurs in reliance upon and in conformity with written information
furnished by such Investor expressly for use in connection with such registration; and each such Investor will pay any legal or other expenses reasonably incurred by any person intended to be
indemnified pursuant to this subsection 1.9(b), in connection with investigating or defending any such loss, claim, damage, liability or action;  provided, however, that the indemnity agreement contained
in this subsection 1.9(b) shall not apply to amounts paid in settlement of any such loss,
claim, damage, liability or action if such settlement is effected without the written consent of the Investor (which consent shall not be unreasonably withheld);  provided further, that in no event shall
any indemnity under this subsection 1.9(b) exceed the gross proceeds from the offering received by such
Investor, except in the case of willful fraud by such Investor. 

        (c)   Promptly
after receipt by an indemnified party under this Section 1.9 of notice of the commencement of any action (including any governmental action), such
indemnified party will, if a claim in respect thereof is to be made against any indemnifying party under this Section 1.9, deliver to the indemnifying party a written notice of the commencement
thereof and the indemnifying party shall have the right to participate in, and, to the extent the indemnifying party so desires, jointly with any other indemnifying party similarly noticed, to assume
the defense thereof with counsel mutually satisfactory to the parties; provided, however, that an indemnified party (together with all other indemnified
parties which may be represented without conflict by one counsel) shall have the right to retain one separate counsel, with the reasonable fees and expenses to be paid by the indemnifying party, if
representation of such indemnified party by the counsel retained by the indemnifying party would be inappropriate due to actual or potential differing interests between such indemnified party and any
other party represented by such counsel in such proceeding. The failure to deliver written notice to the indemnifying party within a reasonable time of the commencement of any such action, if
prejudicial to its ability to defend such action, shall relieve such indemnifying party of any liability to the indemnified party under this Section 1.9, but the omission to so deliver written
notice to the indemnifying party will not relieve it of any liability that it may have to any indemnified party otherwise than under this Section 1.9. 

        (d)   If
the indemnification provided for in this Section 1.9 is held by a court of competent jurisdiction to be unavailable to an indemnified party with respect to any
loss, claim, damage or liability referred to herein, then the indemnifying party, in lieu of indemnifying such indemnified party hereunder, shall contribute to the amount paid or payable by such
indemnified party as a result of such loss, claim, damage or liability in such proportion as is appropriate to reflect the relative fault of the indemnifying party on the one hand and of the
indemnified party on the other in connection with the statements or omissions that resulted in such loss, claim, damage or liability, as well as any other relevant equitable considerations;  provided,
however, that in no event shall any contribution by an Investor under this subsection 1.9(d) exceed the net proceeds from the offering
received by such Investor, except in the case of willful fraud by such Investor. The relative fault of the indemnifying party and of the indemnified party shall be determined by reference to, among
other things, whether the untrue or alleged untrue statement of a material fact or the omission to state a material fact relates to information supplied by the indemnifying party or by the 

4

 

indemnified
party and the parties' relative intent, knowledge, access to information and opportunity to correct or prevent such statement or omission. 

        (e)   Notwithstanding
the foregoing, to the extent that the provisions on indemnification and contribution contained in the underwriting agreement entered into in connection
with an underwritten public offering are in conflict with the foregoing provisions, the provisions in the underwriting agreement shall control. 

        (f)    The
obligations of the Company and Investors under this Section 1.9 shall survive the completion of any offering of Registrable Securities in a Registration
Statement under this Section 1, the termination of this Agreement and otherwise. No indemnifying party, in the defense of any such claim or litigation,
shall, except with the written consent of each indemnified party, consent to entry of any judgment or enter into any settlement which does not include as an unconditional term thereof the giving by
the claimant or plaintiff of a release of the indemnified party from all liability in respect of such claim or litigation. 

        1.10 Reports Under Securities Exchange Act of 1934. With a view to making available to the Investors the benefits of
Rule 144 promulgated under the Act, the Company agrees to: 

        (a)   comply
with the provisions of paragraph (c)(1) of Rule 144; and 

        (b)   file
with the SEC in a timely manner all reports and other documents required of the Company under the Act and the 1934 Act. 

        1.11 Assignment of Registration Rights. Neither this Agreement nor any of the rights of the Investors or the Company may be
assigned by either party to any other party. 

	2.
	Miscellaneous.

        2.1.  Third Party Beneficiaries. Nothing in this Agreement, express or implied, is intended to confer upon any party, other
than the parties hereto, any rights, remedies, obligations or liabilities under or by reason of this Agreement, except as expressly provided in this Agreement. 

        2.2.  Governing Law. This Agreement shall be governed by and construed under the laws of the State of California as applied to
agreements among California residents entered into and to be performed entirely within California. 

        2.3.  Titles and Subtitles. The titles and subtitles used in this Agreement are used for convenience only and are not to be
considered in construing or interpreting this Agreement. 

        2.4.  Notices. Unless otherwise provided herein, all notices required or permitted hereunder shall be in writing and shall be
deemed effectively given: (i) upon personal delivery to the party to be notified, (ii) when sent by confirmed facsimile if sent during the normal business hours of the recipient (if not
sent during the normal business hours of the recipient, then on the next business day); (iii) five days after having been sent by registered or certified mail, return receipt requested, postage
prepaid; or (iv) one day after deposit with a nationally recognized overnight courier, specifying next day delivery, with written verification of receipt. All written communications shall be
addressed to the party to be notified at the address or number applicable to such party appearing on the books of the Company. 

        2.5.  Attorneys' Fees. If any action at law or in equity is necessary to enforce or interpret the terms of this Agreement, the
prevailing party shall be entitled to reasonable attorney's fees, costs and necessary disbursements in addition to any other relief to which such party may be entitled. 

        2.6.  Amendments and Waivers. Any term of this Agreement may be amended and the observance of any term of this Agreement may
be waived (either generally or in a particular instance and either retroactively or prospectively) only with the written consent of the Company and the holders of a majority of the Common Stock (not
including Common Stock issued or issuable upon exercise of the 

5

 

Warrants)
sold pursuant to this Agreement; provided, however, that, the foregoing notwithstanding,  Schedule A to this Agreement shall be supplemented to add
each Additional Investor (as defined in the Purchase Agreement) as of each Additional
Closing (as defined in the Purchase Agreement) as contemplated by Section 1.2(b) of the Purchase Agreement. Any amendment or waiver effected in accordance with this paragraph shall be binding
upon all Investors and the Company. 

        2.7.  Severability. If one or more provisions of this Agreement are held to be unenforceable under applicable law, such
provision shall be excluded from this Agreement and the balance of the Agreement shall be interpreted as if such provision was so excluded and shall be enforceable in accordance with its terms. 

        2.9.  Entire Agreement. This Agreement and the other agreements referenced herein (including any schedules and/or exhibits
hereto and/or thereto) constitute the entire agreement among the parties with respect to the subject matter hereof and thereof and no party shall be liable or bound to any other party in any manner by
any warranties, representations or covenants except as specifically set forth herein or therein. 

        2.10. Counterparts. This Agreement may be executed in one or more counterparts, each of which shall be deemed an original,
but all of which together shall constitute one and the same instrument. Each Additional Investor shall execute a counterpart signature page to this Agreement and become a party to this Agreement
without the need of further signature of approval of any Investor other than the Initial Closing Investor (as contemplated by Section 1.2(b) of the Purchase Agreement). 

[Signature
pages follow] 

6

        The parties hereto have executed this Registration Rights Agreement as of the date first written above. 

	COMPANY:	 	 	 	VISTA MEDICAL TECHNOLOGIES, INC.
	

 	
 	

 	
 	

By:	

/s/  JOHN R. LYON      
 John R. Lyon, President and Chief Executive Officer
	

 	
 	

Address:	
 	

2101 Faraday Ave.

Carlsbad, CA 92008
	 	 	Fax:	 	(760) 603-9170

[COUNTERPART
SIGNATURE PAGE TO REGISTRATION RIGHTS AGREEMENT

OF VISTA MEDICAL TECHNOLOGIES, INC.] 

        The
parties hereto have executed this Registration Rights Agreement as of the date first written above. 

	INVESTORS:	 	 	 
	

 	
 	

 	

/s/  ALBERT GRUNEISEN III      
 Albert Gruneisen III
	

 	
 	

Address:	

1626 Cherokee Road

Louisville, KY 40205
	

 	
 	

Telephone:	

(502) 589-4523

[COUNTERPART
SIGNATURE PAGE TO REGISTRATION RIGHTS AGREEMENT

OF VISTA MEDICAL TECHNOLOGIES, INC.] 

        The
parties hereto have executed this Registration Rights Agreement as of the date first written above. 

	 	 	 	/s/  WILLIAM C. DUGDALE      
 William C. Dugdale
	

 	
 	

Address:	

1907 Mount Vernon Avenue

Wilmington, DE 19806
	

 	
 	

Telephone:	

(302) 777-5445

[COUNTERPART
SIGNATURE PAGE TO REGISTRATION RIGHTS AGREEMENT

OF VISTA MEDICAL TECHNOLOGIES, INC.] 

        The
parties hereto have executed this Registration Rights Agreement as of the date first written above. 

	 	 	 	/s/  TROY N. TOMLIN      
 Troy N. Tomlin
	

 	
 	

Address:	

6156 Montgomery Place

San Jose, CA 95135
	

 	
 	

Telephone:	

(408) 270-8769

[COUNTERPART
SIGNATURE PAGE TO REGISTRATION RIGHTS AGREEMENT

OF VISTA MEDICAL TECHNOLOGIES, INC.] 

        The
parties hereto have executed this Registration Rights Agreement as of the date first written above. 

	 	 	 	/s/  WILLIAM K. DUGDALE      
 William K. Dugdale
	

 	
 	

Address:	

250 Fairview Road

Coatesville, PA 19320
	

 	
 	

Telephone:	

(302) 652-3101

[COUNTERPART
SIGNATURE PAGE TO REGISTRATION RIGHTS AGREEMENT

OF VISTA MEDICAL TECHNOLOGIES, INC.] 

        The
parties hereto have executed this Registration Rights Agreement as of the date first written above. 

	 	 	 	/s/  MARGARET L. DUGDALE      
 Margaret L. Dugdale
	

 	
 	

Address:	

2742 Pierce Street

San Francisco, CA 94123
	

 	
 	

Telephone:	

(415) 673-9585

[COUNTERPART
SIGNATURE PAGE TO REGISTRATION RIGHTS AGREEMENT

OF VISTA MEDICAL TECHNOLOGIES, INC.] 

        The
parties hereto have executed this Registration Rights Agreement as of the date first written above. 

	 	 	 	/s/  DEVON D. HATHAWAY      
 Devon D. Hathaway
	

 	
 	

Address:	

6206 Blackburn Lane

Baltimore, MD 21212
	

 	
 	

Telephone:	

(410) 433-8524

[COUNTERPART
SIGNATURE PAGE TO REGISTRATION RIGHTS AGREEMENT

OF VISTA MEDICAL TECHNOLOGIES, INC.] 

        The
parties hereto have executed this Registration Rights Agreement as of the date first written above. 

	 	 	 	C. GLEN & JOAN DUGDALE
	

 	
 	

 	

/s/  C. GLEN DUGDALE      
 C. Glen Dugdale
	

 	
 	

 	

/s/  JOAN DUGDALE      
 Joan Dugdale
	

 	
 	

Address:	

P.O. Box 4550

Greenville, DE 19807
	

 	
 	

Telephone:	

(302) 656-0529

[COUNTERPART
SIGNATURE PAGE TO REGISTRATION RIGHTS AGREEMENT

OF VISTA MEDICAL TECHNOLOGIES, INC.] 

        The
parties hereto have executed this Registration Rights Agreement as of the date first written above. 

	

 	
 	

 	

/s/  JOAN O. DUGDALE      
 Joan O. Dugdale
	

 	
 	

Address:	

P.O. Box 4550

Greenville, DE 19807
	

 	
 	

Telephone:	

(302) 656-0529

[COUNTERPART
SIGNATURE PAGE TO REGISTRATION RIGHTS AGREEMENT

OF VISTA MEDICAL TECHNOLOGIES, INC.] 

        The
parties hereto have executed this Registration Rights Agreement as of the date first written above. 

	 	 	 	 	MBD GST FBO C. GLEN DUGDALE
	

 	
 	

 	
 	

By:	

/s/  C. GLEN DUGDALE      
 C. Glen Dugdale
	

 	
 	

Address:	
 	

P.O. Box 4550

Greenville, DE 19807
	

 	
 	

Telephone:	
 	

(302) 656-0529

[COUNTERPART
SIGNATURE PAGE TO REGISTRATION RIGHTS AGREEMENT

OF VISTA MEDICAL TECHNOLOGIES, INC.] 

        The
parties hereto have executed this Registration Rights Agreement as of the date first written above. 

	 	 	 	 	B/D TRUST FBO C. GLEN DUGDALE
	

 	
 	

 	
 	

By:	

/s/  C. GLEN DUGDALE      
 C. Glen Dugdale
	

 	
 	

Address:	
 	

P.O. Box 4550

Greenville, DE 19807
	

 	
 	

Telephone:	
 	

(302) 656-0529

[COUNTERPART
SIGNATURE PAGE TO REGISTRATION RIGHTS AGREEMENT

OF VISTA MEDICAL TECHNOLOGIES, INC.] 

        The
parties hereto have executed this Registration Rights Agreement as of the date first written above. 

	 	 	 	 	JOAN CORRIGAN REVOCABLE TRUST
	

 	
 	

 	
 	

By:	

/s/  JOAN CORRIGAN      
 Joan Corrigan, Trustee
	

 	
 	

Address:	
 	

2550 Pierce Street

San Francisco, CA 94115
	

 	
 	

Telephone:	
 	

(415) 346-4666

[COUNTERPART
SIGNATURE PAGE TO REGISTRATION RIGHTS AGREEMENT

OF VISTA MEDICAL TECHNOLOGIES, INC.] 

        The
parties hereto have executed this Registration Rights Agreement as of the date first written above. 

	 	 	 	JOSEPH AND JUDY YAAKOVIAN
	

 	
 	

 	

/s/  JOSEPH YAAKOVIAN      
 Joseph Yaakovian
	

 	
 	

 	

/s/  JUDY YAAKOVIAN      
 Judy Yaakovian
	

 	
 	

Address:	

1020 Foulk Road

Wilmington, DE 19803
	

 	
 	

Telephone:	

(302) 573-4011

[COUNTERPART
SIGNATURE PAGE TO REGISTRATION RIGHTS AGREEMENT

OF VISTA MEDICAL TECHNOLOGIESREGISTRATION RIGHTS 

 
 

Schedule A    
    SCHEDULE OF INVESTORS    
    

Albert
Gruneisen III

William C. Dugdale

Troy N. Tomlin

William K. Dugdale

Margaret L. Dugdale

Devon D. Hathaway

C. Glen & Joan Dugdale

Joan O. Dugdale

MBD GST FBO C. Glen Dugdale

B/D Trust FBO C. Glen Dugdale

Joan Corrigan Revocable Trust

Joseph and Judy Yaakovian 

QuickLinks

Exhibit 4.6

REGISTRATION RIGHTS AGREEMENT

Schedule A SCHEDULE OF INVESTORS

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00068-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00068-of-00352.parquet"}]]